肾脏替代治疗与院外心脏骤停后目标温度管理合并重度急性肾损伤患者死亡风险降低独立相关
该研究为前瞻性收集的多中心观察性队列的回顾性分析,纳入韩国22家医院2015年10月至2018年12月接受目标温度管理的成人院外心脏骤停患者,急性肾损伤按KDIGO标准诊断。最终队列1063例中590例(55.5%)发生急性肾损伤,223例(21.0%)为3期,其中115例(51.6%)接受肾脏替代治疗,最常见方式为连续性肾脏替代治疗(111例,96.5%)。肾脏替代治疗组6个月死亡率低于非肾脏替代治疗组(81% vs 91%,P=0.04),多变量Cox回归显示肾脏替代治疗与3期急性肾损伤患者死亡风险降低独立相关(HR 0.569,95%CI 0.377-0.857,P=0.01)。
要点
- 院外心脏骤停后目标温度管理患者中,3期急性肾损伤接受肾脏替代治疗者6个月死亡率为81%(93/115),未接受者为91%(98/108),P=0.04。
- 多变量Cox回归显示,3期急性肾损伤患者中肾脏替代治疗与6个月死亡风险降低独立相关,HR 0.569(95%CI 0.377-0.857,P=0.01)。
- 肾脏替代治疗组6个月脑功能分类(CPC)1级比例为10.4%(12/115),非肾脏替代治疗组为2.8%(3/108),CPC分布整体P=0.01。
- 肾脏替代治疗最常见方式为连续性肾脏替代治疗(111/115,96.5%),间断血液透析为4/115(3.5%)。
- 该研究为观察性队列的回顾性分析,肾脏替代治疗与死亡风险的关联不等同于因果获益。
适用人群与场景
- 成人院外心脏骤停后接受目标温度管理的患者,来自韩国22家医院2015年10月至2018年12月的前瞻性多中心观察性队列。
- 纳入分析前排除院自发循环恢复后48小时内死亡者及院前已存在慢性肾脏病者,最终队列1063例。
- 研究聚焦其中发生3期急性肾损伤的患者223例(21.0%),其中115例(51.6%)接受肾脏替代治疗。
诊断标准与关键阈值
- 急性肾损伤按肾脏疾病:改善全球结局(KDIGO)标准诊断。
- 急性肾损伤总体发生率为55.5%(590/1063),3期急性肾损伤为21.0%(223/1063)。
处置流程与药物剂量
- 3期急性肾损伤患者中115例(51.6%)接受肾脏替代治疗,最常见方式为连续性肾脏替代治疗(111例,96.5%),其次为间断血液透析(4例,3.5%)。
研究设计与关键结果
- 研究类型为前瞻性收集的多中心观察性队列研究的回顾性分析,覆盖韩国22家医院,最终分析队列1063例,其中3期急性肾损伤223例。
- 主要终点6个月死亡率:肾脏替代治疗组81%(93/115) vs 非肾脏替代治疗组91%(98/108),P=0.04。
- 多变量Cox回归显示肾脏替代治疗与3期急性肾损伤患者死亡风险降低独立相关,HR 0.569(95%CI 0.377-0.857,P=0.01)。
- 6个月CPC分布(非肾脏替代治疗组 vs 肾脏替代治疗组):CPC 1为2.8%(3/108) vs 10.4%(12/115),CPC 2为0.0%(0/108) vs 0.9%(1/115),CPC 3为0.9%(1/108) vs 2.6%(3/115),CPC 4为5.6%(6/108) vs 5.2%(6/115),CPC 5为90.7%(98/108) vs 80.9%(93/115),P=0.01。
证据类型、等级与局限
- 证据类型:前瞻性收集的多中心观察性队列研究的回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该研究提示,在院外心脏骤停后接受目标温度管理并发生3期急性肾损伤的患者中,接受肾脏替代治疗者6个月死亡率低于未接受者(81% vs 91%),且多变量分析显示肾脏替代治疗与死亡风险降低独立相关(HR 0.569)。
- 原文为观察性队列的回顾性分析,肾脏替代治疗与预后的关联不能直接推断为因果获益,也不能据此对所有3期急性肾损伤患者常规启动肾脏替代治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The effect of renal replacement therapy (RRT) on the outcomes of severe acute kidney injury (AKI) after out-of-hospital cardiac arrest (OHCA) is uncertain. This study aimed to evaluate the association of RRT with 6-month mortality in patients with severe AKI treated with targeted temperature management (TTM) after OHCA.
METHODS: This was a retrospective analysis of a prospectively collected multicentre observational cohort study that included adult OHCA patients treated with TTM across 22 hospitals in South Korea between October 2015 and December 2018. AKI was diagnosed using the Kidney Disease: Improving Global Outcomes criteria. The primary outcome was 6-month mortality and the secondary outcome was cerebral performance category (CPC) at 6 months. Multivariate Cox regression analysis was performed to define the role of RRT in stage 3 AKI.
RESULTS: Among 10,426 patients with OHCA, 1373 were treated with TTM. After excluding those who died within 48 h of return of spontaneous circulation (ROSC) and those with pre-arrest chronic kidney disease, our study cohort comprised 1063 patients. AKI developed in 590 (55.5%) patients and 223 (21.0%) had stage 3 AKI. Among them, 115 (51.6%) were treated with RRT. The most common treatment modality among RRT patients was continuous renal replacement therapy (111 [96.5%]), followed by intermittent haemodialysis (4 [3.5%]). The distributions of CPC (1-5) at 6 months for the non-RRT vs. the RRT group were 3/108 (2.8%) vs. 12/115 (10.4%) for CPC 1, 0/108 (0.0%) vs. 1/115 (0.9%) for CPC 2, 1/108 (0.9%) vs. 3/115 (2.6%) for CPC 3, 6/108 (5.6%) vs. 6/115 (5.2%) for CPC 4, and 98/108 (90.7%) vs. 93/115 (80.9%) for CPC 5, respectively (P = 0.01). The RRT group had significantly lower 6-month mortality than the non-RRT group (93/115 [81%] vs. 98/108 [91%], P = 0.04). Multivariate Cox regression analyses showed that RRT was independently associated with a lower risk of death in patients with stage 3 AKI (hazard ratio, 0.569 [95% confidence interval, 0.377-0.857, P = 0.01]).
CONCLUSION: Dialysis interventions were independently associated with a lower risk of death in patients with stage 3 AKI treated with TTM after OHCA.
参考来源
- Choi YH, Lee DH, Oh JH, et al. Renal replacement therapy is independently associated with a lower risk of death in patients with severe acute kidney injury treated with targeted temperature management after out-of-hospital cardiac arrest. Crit Care. 2020. PMID: 32204725. doi:10.1186/s13054-020-2822-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。